Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$29.66
$29.24
$18.72
$38.26
$3.06B2.221.57 million shs1.18 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$145.55
$87.26
$22.28
$176.66
$58.11B1.133.47 million shs14.93 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$28.42
-0.1%
$26.06
$23.58
$29.21
$162.16B0.3434.82 million shs23.78 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
0.00%+0.78%+7.93%-2.66%+42.05%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%+3.71%+145.99%+204.94%+478.96%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%-0.32%+6.43%+10.73%+14.34%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$29.66
$29.24
$18.72
$38.26
$3.06B2.221.57 million shs1.18 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$145.55
$87.26
$22.28
$176.66
$58.11B1.133.47 million shs14.93 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$28.42
-0.1%
$26.06
$23.58
$29.21
$162.16B0.3434.82 million shs23.78 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
0.00%+0.78%+7.93%-2.66%+42.05%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%+3.71%+145.99%+204.94%+478.96%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%-0.32%+6.43%+10.73%+14.34%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2.69
Moderate Buy$49.0065.21% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$76.72-47.29% Downside
Pfizer Inc. stock logo
PFE
Pfizer
2.19
Hold$28.28-0.50% Downside

Current Analyst Ratings Breakdown

Latest PFE, MRNA, and BEAM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
Set Price Target$81.00
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
DowngradeHoldSell
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
DowngradeNeutralSell$40.00 ➝ $81.00
8/31/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C-)Hold (C)
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
UpgradeOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Initiated CoverageHold
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Initiated CoverageOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
UpgradeOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
UpgradeHoldBuy$180.00
8/25/2026
Moderna, Inc. stock logo
MRNA
Moderna
UpgradeUnderperformPeer Perform
8/25/2026
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Reiterated RatingBuy$80.00
(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$139.74M21.92N/AN/A$12.20 per share2.43
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B29.89N/AN/A$22.14 per share6.57
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.59$4.39 per share6.47$15.26 per share1.86
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$79.99M-$0.86N/AN/AN/A-54.75%-30.71%-24.07%11/3/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%11/5/2026 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$0.7637.409.671.916.80%19.63%8.46%11/3/2026 (Estimated)

Latest PFE, MRNA, and BEAM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$1.11-$1.18-$0.07-$1.18$16.37 million$0.49 million
8/4/2026Q2 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.6820$0.77+$0.0880-$0.04$14.40 billion$15.03 billion
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.03-$1.97+$0.06-$1.97$102.93 million$145.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.05%-13.20%226.32%16 Years

Latest PFE, MRNA, and BEAM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/24/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.01%7/24/20267/24/20269/1/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
0.09
14.57
14.57
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18
Pfizer Inc. stock logo
PFE
Pfizer
0.71
1.27
0.96

Institutional Ownership

CompanyInstitutional Ownership
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
99.68%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.80%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
510103.29 million99.36 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable

Recent News About These Companies

This Is What I'd Do With Pfizer Stock Right Now
The Second Act of Biotech
Amundi Sells 7,291,854 Shares of Pfizer Inc. $PFE
Saudi Central Bank Increases Stock Position in Pfizer Inc. $PFE
Rose Capital Advisors LLC Invests $905,000 in Pfizer Inc. $PFE
Pfizer (PFE) and Its Peers Head to Head Analysis
Pfizer Ramps Up Obesity And Eczema Bets, Investors Watch
Wall Street Zen Downgrades Pfizer (NYSE:PFE) to Hold
Pfizer (NYSE:PFE) Downgraded by Wall Street Zen to "Hold"
Pfizer (NYSE:PFE) Shares Down 1.4% - What's Next?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Beam Therapeutics stock logo

Beam Therapeutics NASDAQ:BEAM

$29.66 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Moderna stock logo

Moderna NASDAQ:MRNA

$145.55 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pfizer stock logo

Pfizer NYSE:PFE

$28.42 -0.03 (-0.11%)
As of 09/4/2026 03:58 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.